VARFÖR CRYODERM?

Text: Engelska

Written by David Marcarian, MA

Bio: David Marcarian, MA, founder of Precision Biometrics, and inventor of the revolutionary MyoVision 3G Wirefree PhysioMonitoring™ System is a former NASA researcher. In 1986, Marcarian was awarded a $450,000.00 NIH grant from the National Institutes of Health (NIH) to develop an electrophysiological computer-based device for measuring muscle activity, skin temperature and skin resistance.

In 1989, David founded Precision Biometrics, Inc. for the purpose of providing health care professionals and researchers alike with Surface EMG equipment for electrophysiological measurements. Precision Biometrics is known for providing a rugged, highly reproducible Surface EMG system with the easiest to use software available. Mr. Marcarian is one of the world’s foremost authorities on electrophysiological computer-based devices.

Marcarian won one of the largest PI awards in US history, and established the validity of sEMG in a major State Superior Court Decision. Recently, Dr. John Gerhardt, author of the AMA publication: ”The Practical Guide to Range of Motion Assessment” endorsed the MyoVision 3G product. Marcarian now trains doctors worldwide through his comprehensive training course: ”MyoVision Team Elite.”

CRYODERM® engaged Precision Biometrics to evaluate the effectiveness of CRYODERM® Cryotherapy Spray™, on hypertonic muscles, using our MyoVision 3G Wirefree Syste.

Procedure:

The MyoVision Static Surface EMG system (Model 3G) was used to test a patient complaining of muscle tension and pain in the right cervical region C2 to C7 and right lower lumbar. MyoVision is the optimal tool for testing, as it is very sensitive, performs the test in a standing neutral position (weight bearing tests are more demonstrative (as in X-Ray), and is the premier tool for SEMG testing since 1989.

Reading the MyoVision graphs below are simple. The device is similar to an EKG in that it measures a summation of the motor unit firing (or depolarizations) beneath the skin where the electrodes are placed. Electrodes are touched down momentarily on the skin at C2, C4, C6 and at every other level of the spine down to L5. The bars shown are proportional to muscle activity: The higher the muscle activity, the further the bars protrude from the spine. Readings are in microvolts (millionths of a volt).

Static SEMG Testing

Static SEMG Testing

MyoVision 3G Wirefree system

MyVision 3G WireFree System

The patient was tested in a standing position. After the initial test the cervical and lower lumbar spine were treated unilaterally with CRYODERM™ in the areas that showed higher muscle activity, indicating hyper tonicity.

The following results were noted:

1. Muscle activity dropped significantly in the areas treated with CRYODERM® where muscle tension had previously tested high. In fact the reduction in muscle firing post treatment averaged 44.6 % in the cervical region and 55.08% in the lower lumbar, bringing it well within the normal range of the left side pre-testing numbers. Unheard of results for a topical preparation! ”If I had not performed the testing myself, I would probably not have believed the results.” (Marcarian)

2. Muscle tension increased on the opposite side in both the cervical and lumbar spine, which is a common response that we see when the opposite side experiences dramatic release. The muscles on the opposing side contract to compensate for the release. Based on clinical experience it is common to see this compensation pattern subside, and a balancing to occur within a few hours. Additionally, treating the area bilaterally should eliminate or greatly reduce this affect.

Research Posttreatment

Pre Treatment MyoVision Exam

Research Pretreatment

Post Treatment MyoVision Exam

Conclusion:

After careful evaluation and under controlled circumstances using the MyoVision SEMG System it was determined that treating painful, swollen, hypertonic areas with CRYODERM® showed significant reduction in muscle activity, thereby aiding in the release of hyper tonic muscles and a breaking of the pain spasm cycle. Since our initial testing I have spoken with several Doctors who have found the same results. Additionally many of these Doctors use CRYODERM® pre adjustment to dull the proprioceptors in order to lessen the response from muscle spindle cells, during and post adjustment (mimicking MUA–manipulation under anesthesia).

Doctors are finding that the utilization of the MyoVision in conjunction with CRYODERM® and Chiropractic adjustments provides more effective, longer lasting results that can be visually seen by the patient. Using MyoVision assists the Doctor to more accurately apply CRYODERM® and helps in tracking the effectiveness of treatment with regards to the utilization of CRYODERM® and adjustments. It is therefore my opinion that CRYODERM® is an extremely effective drug and an excellent adjunct to Chiropractic and other physical modalities.

Proven Anti-inflammatory

CRYODERM’S® KEY INGREDIENTS are clinically proven to dilate blood vessels, inhibit inflammation, platelet adhesion, and oxidative damage through the production of Nitric Oxide and cGMP.

How it works

Research has demonstrated that the ingredients in CRYODERM stimulate nitric oxide (NO) formation through activation of Ca2+/calmodulin-dependent protein kinase (CaM kinase). Nitric oxide, in turn, binds to and activates guanylyl cyclase. This enzyme catalyzes the dephosphorylation of GTP to cyclic GMP (cGMP), which serves as a second messenger for signaling smooth muscle relaxation.

Vascular effects of NO:

CRYODERM Stimlate Nitric Oxide

  • Direct vasodilation (flow dependent and receptor mediated)
  • Indirect vasodilation by inhibiting vasoconstrictor influences (e.g., inhibits angiotensin II and sympathetic vasoconstriction)
  • Anti-thrombotic effect – inhibits platelet adhesion to the vascular endothelium
  • Anti-inflammatory effect – inhibits leukocyte adhesion to vascular endothelium;
  • Anti-proliferative effect – inhibits smooth muscle hyperplasia
  • Scavenges free radicals, improving cellular health

cGMP: Cyclic GMP induces smooth muscle relaxation by multiple mechanisms including

  • Increased intracellular cGMP, which inhibits calcium entry into the cell, and decreases intracellular calcium concentrations.
  • Activates K+ channels, which leads to hyperpolarization and relaxation
  • Stimulates a cGMP-dependent protein kinase that activates myosin light chain phosphatase, the enzyme that dephosphorylates myosin light chains, which leads to smooth muscle relaxation.
  • Induces smooth muscle relaxation
  • Inhibits blood clotting (platelet adhesion).

CRYODERM Acts on Receptors

Research Shows That Key Ingredients In CRYODERM Also Act On Receptors In The Blood Vessels. These Key Ingredients Act to Restore Tissue Homeostasis.

CRYODERM constricts blood vessels when they are over-dilated

Blood Vessel Receptor

When your muscles or joints are inflamed, such as after trauma, exertion, or in arthritis, the blood vessels become leaky and let plasma, white blood cells, and cytokines-the so-called ”inflammatory soup” out into the surrounding tissue. The tissue becomes red, warm, swollen, and painful. CRYODERM’S® proprietary formulation counteracts the vasodilatory effects of the inflammatory mediators making blood vessels contract. This reduces swelling, redness, inflammation, eliminates pain, discomfort and restores the tissue homeostasis.

CRYODERM dilates blood vessels when they are in spasm

Blood Vessel Receptor

When your muscles are in spasm, the blood vessels are constricted, reducing the blood flow to the area and depriving the tissue of the vital oxygen. In this scenario CRYODERM’S® proprietary formulation causes relaxation of blood vessels and a reduction in sympathetic nerve-mediated contraction. CRYODERM® helps restore the natural balance by dilating the blood vessels, thus improving microcirculation, tissue oxygen supply, removing the toxic by-products of metabolism, resolving interstitial acidosis and speeding up tissue healing.

Summary

CRYODERM® aids in regulating blood flow depending on the tissue state, restoring natural homeostasis.

What they found:

A transient receptor potential channel that was previously believed to be found only in a subpopulation of sensory neurons, was recently identified in blood vessels. Isometric contraction studies on endothelium-denuded relaxed vessels found small contractions on application of CRYODERM’S® Key Ingredients. However, these ingredients caused relaxation of vessels precontracted with KCl (60 mM) or the α-adrenoceptor agonist phenylephrine (2 µM) and a reduction in sympathetic nerve-mediated contraction. Thus, these key CRYODERM® ingredients play multiple functional roles, likely to be in a tissue- and activation state-dependent manner, producing opposite effects, causing vasoconstriction or vasodilatation, depending on previous vasomotor tone.

References:

  • Am J Physiol Heart Circ Physiol. 2009 June; 296(6): H1868–H1877. Christopher D. Johnson, Donal Melanaphy, Andrew Purse, Susan A. Stokesberry, Paula Dickson, and Alexander V. Zholos. Transient receptor potential melastatin 8 channel involvement in the regulation of vascular tone.
  • Am J Physiol Heart Circ Physiol. 2009 June; 296(6): H1868–H1877. Cardiovascular Biomedical Research Centre, School of Medicine, Dentistry and Biomedical Sciences, Medical Biology Centre, Queen’s University, Belfast, United Kingdom.

Dose Dependent Outcome

MORE MENTHOL MEANS LESS PAIN.

MENTHOL PRODUCES DOSE-DEPENDENT ANALGESIA. STUDIES SHOW THAT HIGHER CONCENTRATIONS OF MENTHOL PRODUCE GREATER PAIN RELIEF!

Does 3.5% versus 10% make a difference?

Studies showed that natural (-)-Menthol (l-menthol, natural menthol derived from peppermint oil) diminishes one’s perception of pain in a dose-dependent manner. In one study researchers found that the subject’s pain threshold was increased when higher concentrations of l-menthol were applied centrally or peripherally.

Scientists from the Departments of pharmacology of the University of Florence (Florence, Italy), and from the Department of Pharmacology of Natural Substances and General Physiology (Rome, Italy) investigated the analgesic properties of (l)- and (d)-menthol and observed the presence of stereoselectivity: (l)-menthol (natural menthol derived from peppermint oil) was able to increase the pain threshold whereas (d)-menthol (synthetic menthol) was completely devoid of any analgesic effect. Scientists from Centre for Neuroscience Research and Membrane Biology Group, Centre for Integrative Physiology, Edinburgh, United Kingdom, came to similar conclusions in their experiments with (l) – and (d)-menthol: Concentration-dependent effects on pain threshold were observed in both studies.

The results indicated that (-)-menthol is endowed with analgesic properties mediated through a selective activation of ?-opioid receptors and Group II/III metabotropic glutamate receptors (mGluRs).

The antinociception induced by (-)-menthol (l-menthol) was comparable to that exhibited by morphine.

Conclusion:

Topical analgesic products with 10% menthol are more potent and produce greater pain relief than other products with lower menthol concentration.

PRODUCT COMPARISON

Topical Analgesic Menthol %
CRYODERM Gel 10%
Biofreeze Gel 3.5%
Sombra Original 3%
Orthogel 3.5%

References:

  • Nicoletta Galeotti, Lorenzo Di Cesare Mannelli, Gabriela Mazzanti, Alessandro Bartolini and Carla Ghelardini. Menthol: a natural analgesic compound. Neuroscience Letters Volume 322, Issue 3, 12 April 2002, Pages 145-148.
  • Proudfoot CJ, Garry EM, Cottrell DF, et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 2006; 16: 1591e1605.
  • Cryoderm-how it works. www.cryoderm/research.com

Effects on Chemo Induced Neuropathy

ONE OF THE KEY INGREDIENTS IN CRYODERM
REVERSES CHEMOTHERAPY-INDUCED
PERIPHERAL NEUROPATHY AND ENABLES FURTHER EFFECTIVE CHEMOTHERAPY DELIVERY.

Multiple case reports have been published recently describing the revolutionary discovery that will help alleviate severe chemotherapy-induced peripheral neuropathy and to allow further life-prolonging chemotherapy.

Chemotherapy-induced peripheral neuropathy can be a major dose-limiting side effect and leave some cancer patients with long-term pain and functional disability. In some cases, the neuropathy can be so severe as to preclude further life-prolonging chemotherapy.

Case 1

In the article, Storey and co-workers (Edinburgh Cancer Research UK Centre, University of Edinburgh, United Kingdom) report a case of painful, carboplatin-induced peripheral neuropathy in a 71-yearold woman with a four and a half year history of Stage 4 epithelial ovarian cancer.

The woman presented with Grade 3 neurosensory toxicity and complaints of paresthesias, pain, weakness in her hands and difficulty with motor tasks. Amitriptyline 10 mg nightly helped the pain slightly, but she did not tolerate an increased dose of 25 mg.

Her CA-125(marker for ovarian cancer recurrence) was increasing again, but it was felt that her Grade 3 peripheral neuropathy would likely preclude her from further life-saving platinum or taxane therapy.

The authors treated her with topical application of the CRYODERM’s® active ingredient applied over the upper extremities and the skin overlying the corresponding nerve roots. Detailed pain assessment was performed before the treatment, with further assessments 90 minutes after the application, then 2, 6, 10, and15 weeks later.

Results:

There was decreased pain in response to suprathreshold stimulus. The patient continued the treatment twice daily, and these changes were maintained at 2 weeks when she also reported less pain and improved function. By six weeks, the mechanical detection and pain thresholds had improved, and the area of abnormal sensation to light touch, cool, and warm stimuli had markedly decreased. By 10 weeks, her total Brief Pain Inventory score reduced from 31 to 10, and by 15 weeks, she was able to fasten buttons, undo jewelry clasps, and was no longer dropping things. When treatment was continued during chemotherapy, the peripheral neuropathy did not deteriorate.

Case 2

Colvin et al (Centre for Neuroscience Research, Departments of Hematology, Edinburgh, Scotland) report a case of severe bortezomib-induced neuropathy in a 69-year-old man with a 39-month history of multiple myeloma. After his disease relapsed, bortezomib was commenced as third-line antimyeloma treatment. Unfortunately, after two cycles of bortezomib, the patient complained of paresthesias, numbness, and “lightning-like” pains in both hands, which did not resolve despite a 50% dose reduction for the third cycle.

A month later, he developed an extremely painful peripheral neuropathy (grade 4) in his lower limbs. The predominant feature was severe burning, with significant sleep disturbance, high levels of distress, and reduced general function, such that he was virtually bed-bound. Bortezomib was therefore discontinued.

Treatment for neuropathic pain with traditional systemic agents was limited by significant adverse effects.

The patient was treated with CRYODERM’s® active ingredient topically. It was applied to the lower limbs and to the skin over the lumbosacral region of the spine corresponding with the affected nerve roots, with a detailed pain assessment before the treatment, 90 minutes after treatment, and then 2 weeks later.

Results:

Profound changes in Quantitative Sensory Testing were detected 90 minutes after treatment. There was a marked increase in mechanical pain threshold with decreased pain in response to suprathreshold stimulus (VAS score changed from 8 to 2 for both right and left side) and complete reversal of wind-up (VAS reduced from 8 to 0). The patient was able to walk without a stick for the first time since the lower limb neuropathy started. These changes were consistently maintained at the 2-week assessment. The patient continued the treatment twice daily. After 5 days, he reported a sustained improvement in pain control, sleep, mobility, general function, and mood. This was maintained at 2 weeks with his total Brief Pain Inventory score reduced from 56 to 14 and his Hospital Anxiety and Depression scores reduced from 22 to 16. His hand symptoms, which were not treated, remained unchanged, suggesting no spontaneous resolution of his neuropathy.

Conclusions:

Effective treatment of chemotherapy-induced neuropathy with one of CRYODERM’s® key active ingredients allowed continued life-prolonging treatment with good clinical response and no adverse effect!

References:

  • Dawn J. Storey BMedSci, BMBS, MD, Lesley A. Colvin BSc (Hons), MBChB, PhD, Melanie J. Mackean MBChB, MD, Rory Mitchell PhD, Susan M. Fleetwood-Walker PhD and Marie T. Fallon MBChB, MD. Reversal of Dose-Limiting Carboplatin-Induced Peripheral Neuropathy with TRPM8 Activator, Menthol, Enables Further Effective Chemotherapy Delivery. Journal of Pain and Symptom Management. Volume 39, Issue 6, June 2010, Pages e2-e4.
  • Proudfoot CJ, Garry EM, Cottrell DF, et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 2006; 16: 1591e1605.
  • Colvin LA, Johnson PRE, Mitchell R, Fleetwood-Walker SM, Fallon MT. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, Menthol. J Clin Oncol 2008; 26:4519e4520.

Research & Development

CRYODERM® is constantly researching, testing, and improving formulas that utilize the latest discoveries in organic natural substances. Biologists have discovered less than 5% of the benefits that come from plants on our planet. CRYODERM® stands ready to utilize the latest discoveries in the natural world to consistently improve and create new formulations.

In addition to pre-clinical testing on human volunteers, we have added a very important new dimension, using blood, urine and saliva testing, along with Applied Kinesiology. These effective methods provide superior factual data.

lab worker looking into microscopeLloyd List, President of CRYODERM®, has almost two decades of experience researching and applying topical analgesics for pain management and exercise physiology.

Our staff includes a team of specialists including Naturopaths, Pharmacists, Bio Chemists with experience in topically applied products, research and development, quality assurance, and regulatory affairs including FDA CGMP (Current Good Manufacturring Practice) compliance, USDA NOP (Natural Organic Program) and EU Reach Compliance (European Commission on the Environment). Another asset to our team is a specialist in biological plant engineering who is capable of observing and identifying active properties for their beneficial effects.

We also have a review panel of M.D.’s and Chiropractic Physicians who contribute in the development of new products for maximum safety and effectiveness. Other contributors include independent researchers investigating new plant-based nutrients from around the world.

Uppdaterar…
  • Du har inga produkter i varukorgen.